Welcome to the Migraine Learning Zone. Migraine is classified by the International Headache Society as one of the four primary headache disorders and has several different treatment options. With no biomarkers or medical tests available, diagnosis of migraine can be a lengthy process, yet receiving the right treatment and care is of paramount importance to patients suffering from the disabling symptoms associated with this neurological condition.
The Migraine Learning Zone contains the latest recommendations for all aspects of patient care, including diagnosis, acute and preventive migraine treatment options, as well as insights into the novel treatments currently in development.
Discover detailed migraine awareness with/without aura, HALT index, pathophysiology and the trigeminal system, symptoms including visual disturbances and nausea and diagnosis from the International Classification of Headache Disorders 3 (ICHD-3).
Discover acute and preventive migraine treatment options following the AAN and AHS guidelines that include NSAIDs, triptans, ergotamine derivatives, opioids, beta-blockers, calcium channel blockers and tricyclic antidepressants. Future treatments detail CGRP antagonists.
National and international guidelines on all aspects of migraine management including the European Headache Federation (EHF), the European Federation of Neurological Sciences (EFNS) and the International Headache Society (IHS).
Review the terms used in the Migraine Knowledge Centre, along with their definitions including cortical spreading depression, Headache-Attributed Lost Time index (HALT), Hemiplegic migraine and vagus nerve stimulation.
Consult the events calendar for upcoming scientific meetings relevant to migraine and follow links to event websites, featuring the American Academy of Neurology, the American Headache Society and the Migraine Trust International Symposium.